🧬Tidera Health

Tidera provides educational trial discovery tools and does not provide medical advice or determine eligibility. Always discuss options with your care team.

DermatologyICD-10: L28.1

Find Recruiting Clinical Trials for Prurigo Nodularis

Search IL-31, IL-4/13, and neural itch pathway trials for prurigo nodularis — matched to your nodule count and treatment history.

🔍 Search Prurigo Nodularis Trials →

About Prurigo Nodularis

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely itchy nodules distributed across the body, driven by a dysregulated itch-scratch cycle and type 2 inflammation overlapping with atopic dermatitis. Dupilumab (Dupixent) received FDA approval for PN in 2022. Nemolizumab — an anti-IL-31Rα antibody — received FDA approval for PN in 2024. The active trial landscape now targets IL-13, IL-4Rα/IL-13, and neural itch pathways.

What Types of Prurigo Nodularis Clinical Trials Exist?

PN trials typically require a minimum number of nodules (e.g., ≥20), documented prior treatment failure, and use validated outcome measures including IGA-PN (Investigator Global Assessment), NRS Itch (0–10 scale for worst itch), and PPSS (Peak Prurigo Symptom Score). Most moderate-to-severe trials require NRS Itch ≥7 or IGA-PN ≥3.

Find Recruiting Prurigo Nodularis Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Prurigo Nodularis Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for prurigo nodularis?▾
Recruiting PN trials include anti-IL-13 antibodies, next-generation IL-4Rα/IL-13 dual blockers, oral JAK inhibitors, kappa-opioid receptor agonists (targeting itch pathways), and long-term safety extensions of dupilumab and nemolizumab. Most require moderate-to-severe disease and prior treatment failure.
What severity tools are used in prurigo nodularis trials?▾
PN trials use IGA-PN (Investigator Global Assessment), NRS Itch (0–10 scale for worst itch in 24h), PPSS (Peak Prurigo Symptom Score), nodule count, and DLQI (Dermatology Life Quality Index). Most moderate-to-severe trials require NRS Itch ≥7 or IGA-PN ≥3.
Can I join a PN trial if I already use dupilumab or nemolizumab?▾
It depends on the trial. Some trials specifically enroll patients with inadequate response to dupilumab or nemolizumab. Others require biologic-naive patients. Always check the specific eligibility criteria and discuss washout requirements with the research coordinator.

Related Conditions

Atopic DermatitisChronic Spontaneous UrticariaPsoriasis

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.